If you currently use one, and the value of that discount is worth more than potential Part D benefits, opt out of Part D
For growth hormone deficiency specifically: This is the medical indication CJC-1295 and ipamorelin gesture at without ever quite addressing
TUE guidance documents including new regulations on glucocorticoids In order to assist physicians and athletes, in the last few weeks, WADA published the following guidance documents on managing TUEs to include the new regulations on glucocorticoids: General document on glucocorticoids and TUEs Checklists for athletes and treating physicians on a number of medical conditions for which glucocorticoids may be used TUE Physician Guidelines for TUE Committees on how to evaluate TUE requests for glucocorticoids for different medical conditions Educational resources In addition to the guidance documents listed above, WADA has provided a number of educational resources as part of its Code Implementation Support Program (CISP), which can be accessed on the Agencys Anti-Doping Education and Learning Platform (ADEL)
Fasting glucose and HbA1c: Baseline and at 8 weeks
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A